Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB
Mandate

Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB

September 03, 2018 M&A

Vinge together with the Norwegian law firm Schjodt advises the Norwegian pharmaceuticals company Ultimovacs AS in connection with its acquisition of the immunotherpay business of the Uppsala based company Immuneed AB.

The business focuses on the development of vaccine for the treatment and potential prevention of cancer.

Vinge's team consisted primarily of the partner Jonas Johansson and the associates Carl Sander and Fredric Reismüller.

Related

Vinge advises Dunlop Aircraft Tyres in connection with its issuance of USD 93 million senior secured bonds

 Vinge has advised Dunlop, in connection with its issuance of senior secured bonds in the amount of USD 93 million, under a total framework of USD 120 million.
January 08, 2026

Vinge advises Stockwik Förvaltning in conjunction with the acquisition of Labino

 Vinge has advised Stockwik Förvaltning in connection with its acquisition of Labino, a world-leading Swedish manufacturer of industrial UV light fixtures.
December 19, 2025

Vinge advises Revivo Group in conjunction with the acquisition of Nordisk Ytbehandling

 Vinge has advised Revivo Group in connection with the acquisition of Nordisk Ytbehandling, a well-established contracting company based in Nyköping specialising in blasting as well as anti-corrosion and fire protection painting, with a solid customer base within the industrial and infrastructure sectors.
December 19, 2025